Apolipoprotein KV domain (67 – 77) YTMNPRKLFDY-acid

  • Description

  • Application Data

Description

Apolipoprotein KV domain (67 – 77) corresponds to the active region of human apolipoprotein A (ApoA) kringle5- like domain; this sequence can inhibit angiogenesis. 

See full description

Application Data

Catalogue number crb1000161
Molecular Weight 1447.66
Sequence (one letter code) YTMNPRKLFDY-acid
Sequence (three letter code)

H-Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr-OH

Purity >95%
References

Kalaivani and Jaleel (2020). Apolipoprotein(a), an enigmatic anti-angiogenic glycoprotein in human plasma: A curse or cure? Pharmacol Res., 58: 104858. PMID: 32430285.

 

Yi et al., (2009). A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int. J. Cancer Res., 124(4): 843. https://doi.org/10.1002/ijc.24027. 

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Vascular lipid deposition and altered lipid profiles are typical when unregulated angiogenesis is occurring, it is often seen in vascular disorders such as cancer and atherosclerosis. Apolipoprotein a (ApoA) functions as part of the lipid transporter complex high-density lipoproteins (HDL) to ensure lipid homeostasis and therefore the balance of angiogenesis. Within ApoA the Kringle5 (KV) domain (67 – 77), also known as KV11, has been identified as the region of ApoA that exerts anti-angiogenic effect. KV11 was shown in tumour cells to inhibit angiogenesis and consequently inhibits tumour progression. KV11 targets the angiogenesis c-Src/ERK pathway by blocking the activation signals received from vascular endothelial growth factor (VEGF). KV11 provides a new research potential for an anti-angiogenesis and anti-tumour therapeutic agent.

Apolipoprotein KV domain (67 – 77)

Cat No.Pack SizePriceQty.
1mg£110.00
0.5mg£85.00
Bulk Quote